See more : Spandana Sphoorty Financial Limited (SPANDANA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of MusclePharm Corporation (MSLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MusclePharm Corporation, a leading company in the Packaged Foods industry within the Consumer Defensive sector.
- China Investment Fund Company Limited (0612.HK) Income Statement Analysis – Financial Results
- Qell Acquisition Corp. (QELLU) Income Statement Analysis – Financial Results
- Lloyds Banking Group plc (LYG) Income Statement Analysis – Financial Results
- EQ Inc. (EQ.V) Income Statement Analysis – Financial Results
- Artnature Inc. (7823.T) Income Statement Analysis – Financial Results
MusclePharm Corporation (MSLP)
About MusclePharm Corporation
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada. On December 15, 2022, MusclePharm Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Nevada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.04M | 64.44M | 79.67M | 88.11M | 102.16M | 132.50M | 166.86M | 177.39M | 110.88M | 67.06M | 20.84M | 4.05M | 1.02M | 0.00 | 7.98K |
| Cost of Revenue | 44.67M | 44.83M | 70.98M | 69.72M | 71.71M | 88.03M | 109.93M | 121.38M | 77.69M | 52.73M | 14.47M | 2.80M | 922.97K | 0.00 | 0.00 |
| Gross Profit | 5.37M | 19.61M | 8.69M | 18.39M | 30.45M | 44.47M | 56.93M | 56.01M | 33.19M | 14.33M | 6.37M | 1.24M | 94.95K | 0.00 | 7.98K |
| Gross Profit Ratio | 10.73% | 30.43% | 10.91% | 20.88% | 29.80% | 33.56% | 34.12% | 31.57% | 29.94% | 21.37% | 30.56% | 30.71% | 9.33% | 0.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 893.00K | 751.00K | 642.00K | 1.87M | 4.25M | 4.00M | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 16.33M | 20.42M | 22.54M | 25.58M | 39.71M | 57.35M | 43.34M | 30.84M | 14.63M | 22.59M | 19.49M | 822.32K | 20.26K | 1.00M |
| Selling & Marketing | 4.39M | 507.00K | 2.49M | 2.94M | 9.35M | 10.65M | 26.99M | 28.05M | 15.53M | 8.43M | 0.00 | 0.00 | 1.07M | 4.17K | 1.62K |
| SG&A | 4.39M | 16.84M | 22.90M | 25.48M | 34.94M | 50.36M | 84.33M | 71.39M | 46.37M | 23.06M | 22.59M | 19.49M | 1.89M | 24.43K | 1.00M |
| Other Expenses | 9.89M | 9.87M | 14.00M | 0.00 | 1.88M | 35.32M | 83.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.40K | -48.85K | 0.00 |
| Operating Expenses | 14.28M | 16.84M | 23.80M | 26.23M | 37.45M | 52.23M | 88.59M | 75.39M | 47.49M | 23.06M | 22.59M | 19.49M | 1.91M | -24.43K | 1.00M |
| Cost & Expenses | 58.96M | 61.67M | 94.77M | 95.95M | 109.16M | 140.26M | 198.51M | 196.77M | 125.17M | 75.79M | 37.06M | 22.30M | 2.83M | 24.43K | 1.00M |
| Interest Income | 0.00 | 675.00K | 383.00K | 18.00K | -837.00K | 0.00 | 0.00 | 223.00K | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.46M | 1.70M | 3.76M | 3.80M | 3.26M | 1.64M | 779.00K | 201.00K | 783.32K | 7.34M | 3.71M | 480.59K | 102.39K | 0.00 | 0.00 |
| Depreciation & Amortization | 331.00K | 465.00K | 659.00K | 849.00K | 1.46M | 2.13M | 2.82M | 1.98M | 708.98K | 475.32K | 171.59K | 787.20K | 7.95K | 0.00 | 0.00 |
| EBITDA | -8.91M | 5.33M | -14.43M | -6.01M | -7.19M | 610.00K | -48.16M | -11.62M | -14.30M | -8.74M | -19.40M | -18.30M | -1.80M | -24.43K | -995.89K |
| EBITDA Ratio | -14.12% | 8.27% | -18.11% | -6.82% | -5.98% | 0.46% | -28.86% | -6.55% | -14.53% | -16.62% | -93.09% | -452.19% | -177.14% | 0.00% | -12,481.39% |
| Operating Income | -7.40M | 4.86M | -15.09M | -6.86M | -7.57M | -1.52M | -50.97M | -13.60M | -16.82M | -11.62M | -19.57M | -19.09M | -1.81M | -24.43K | -995.89K |
| Operating Income Ratio | -14.78% | 7.54% | -18.94% | -7.78% | -7.41% | -1.14% | -30.55% | -7.67% | -15.17% | -17.33% | -93.91% | -471.64% | -177.92% | 0.00% | -12,481.39% |
| Total Other Income/Expenses | -5.48M | 564.00K | -3.76M | -3.80M | -3.64M | 5.50M | -779.00K | -201.00K | -783.32K | -7.34M | -3.35M | -836.91K | -6.45K | 0.00 | 0.00 |
| Income Before Tax | -12.87M | 3.17M | -18.84M | -10.66M | -10.83M | -3.16M | -51.75M | -13.80M | -17.60M | -18.95M | -22.92M | -19.93M | -1.82M | -24.43K | -995.89K |
| Income Before Tax Ratio | -25.73% | 4.91% | -23.65% | -12.09% | -10.60% | -2.38% | -31.02% | -7.78% | -15.88% | -28.26% | -109.99% | -492.32% | -178.55% | 0.00% | -12,481.39% |
| Income Tax Expense | 8.00K | -19.00K | 86.00K | 100.00K | 142.00K | 318.00K | 105.00K | 33.00K | 115.48K | 7.34M | 3.71M | 480.59K | 102.39K | 0.00 | 0.00 |
| Net Income | -12.88M | 3.19M | -18.93M | -10.76M | -10.97M | -3.48M | -51.86M | -13.83M | -17.72M | -26.29M | -26.63M | -20.41M | -1.92M | -24.43K | -995.89K |
| Net Income Ratio | -25.74% | 4.94% | -23.76% | -12.21% | -10.74% | -2.62% | -31.08% | -7.80% | -15.98% | -39.20% | -127.80% | -504.19% | -188.61% | 0.00% | -12,481.39% |
| EPS | -0.31 | 0.08 | -0.92 | -0.72 | -0.79 | -0.26 | -3.81 | -1.25 | -2.46 | -18.02 | -80.45 | -421.77 | -3.74K | -47.52 | -1.94K |
| EPS Diluted | -0.31 | 0.08 | -0.92 | -0.72 | -0.79 | -0.26 | -3.81 | -1.25 | -2.46 | -18.02 | -80.45 | -421.77 | -3.74K | -47.52 | -1.94K |
| Weighted Avg Shares Out | 41.17M | 41.17M | 20.48M | 15.02M | 13.88M | 13.44M | 13.62M | 11.07M | 7.19M | 1.46M | 331.03K | 48.38K | 514.00 | 514.00 | 514.00 |
| Weighted Avg Shares Out (Dil) | 41.17M | 41.17M | 20.48M | 15.02M | 13.88M | 13.44M | 13.62M | 11.07M | 7.19M | 1.46M | 331.03K | 48.38K | 514.00 | 514.00 | 514.00 |
MusclePharm taps former Rockstar Energy executive to build National Distribution Network and Sales Team for MP Performance Energy beverages
MusclePharm Announces Record Breaking Fourth Quarter and Fiscal Year 2020 Financial Results; Primed for Return to Growth
MusclePharm Corporation to Hold 2017 Fourth Quarter and Full Year Conference Call on March 28, 2018
MusclePharm Schedules 2015 Third Quarter Financial Results
Source: https://incomestatements.info
Category: Stock Reports